<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00235248</url>
  </required_header>
  <id_info>
    <org_study_id>P991205</org_study_id>
    <nct_id>NCT00235248</nct_id>
  </id_info>
  <brief_title>Aortic Arch Related Cerebral Hazard Trial (ARCH)</brief_title>
  <acronym>ARCH</acronym>
  <official_title>Prevention of New Vascular Events in Patients With Brain Infarction or Peripheral Embolism and Thoracic Aortic Plaques ≥ 4 mm in Thickness in the Aortic Arch or Descending Aortic Upstream to the Embolized Artery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Health and Medical Research Council, Australia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The ARCH is a controlled trial with a sequential design and with a prospective, randomized,
      open-label, blinded-endpoint (PROBE) methodology. The objective is to compare the efficacy
      and tolerance (net benefit) of two antithrombotic strategies in patients with
      atherothrombosis of the aortic arch and a recent (less than 6 months) cerebral or peripheral
      embolic event.

      Hypothesis:

      The association of clopidogrel 75 mg/d plus aspirin 75 mg/d is 25% more effective than an
      oral anticoagulant (target International Normalized Ratio [INR] 2 to 3) in preventing brain
      infarction, brain hemorrhage, myocardial infarction, peripheral embolism, and vascular death.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with Transient Ischemic attack or brain infarction of unknown cause (no ipsilateral
      internal carotid artery origin stenosis greater than 70%, no ipsilateral severe intracranial
      stenosis of an artery supplying the infarcted area, no definite cardiac source of embolism)
      in the preceding 6 months and atherosclerotic plaques.

      ≥ 4 mm in the aortic arch, or patients with a peripheral event (e.g. renal infarct) in the
      preceding 6 months and plaque ≥ 4 mm in the thoracic aorta above the origin of the embolized
      artery.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2002</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>New vascular events assessed every 4 months including stroke, myocardial infarction (MI), peripheral events, and vascular death</measure>
    <time_frame>every 4 months</time_frame>
    <description>New vascular events assessed every 4 months including stroke, myocardial infarction (MI), peripheral events, and vascular death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recurrent brain infarction</measure>
    <time_frame>during the trial</time_frame>
    <description>Recurrent brain infarction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>brain infarction and transient ischemic attack (TIA)</measure>
    <time_frame>during the studing</time_frame>
    <description>brain infarction and transient ischemic attack (TIA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>new vascular events and revascularization procedure</measure>
    <time_frame>during the trial</time_frame>
    <description>new vascular events and revascularization procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>vascular death</measure>
    <time_frame>during the trial</time_frame>
    <description>vascular death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>death from all causes</measure>
    <time_frame>during the trial</time_frame>
    <description>death from all causes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>combination of primary end-point and TIA</measure>
    <time_frame>during the trial</time_frame>
    <description>combination of primary end-point and TIA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>revascularization procedures</measure>
    <time_frame>during the trial</time_frame>
    <description>revascularization procedures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>urgent rehospitalization for ischemic</measure>
    <time_frame>during the trial</time_frame>
    <description>urgent rehospitalization for ischemic</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">350</enrollment>
  <condition>Brain Infarction</condition>
  <condition>Transient Ischemic Attack</condition>
  <condition>Embolism</condition>
  <arm_group>
    <arm_group_label>Clopidogrel-aspirin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Clopidogrel-aspirin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Warfarin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Warfarin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Warfarin</intervention_name>
    <description>Warfarin</description>
    <arm_group_label>Warfarin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel-aspirin</intervention_name>
    <description>Clopidogrel-aspirin</description>
    <arm_group_label>Clopidogrel-aspirin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients of both sexes aged ≥ 18 years with the following 4 inclusion criteria:

          -  One of the 3 following ischemic events in the preceding 6 months:

               -  Transient ischemic attack (TIA)

               -  Non-disabling brain infarcts:

                    -  Inclusion within 6 months after onset

                    -  Duration of symptoms and signs greater than 24 hours

                    -  Neurological signs at the time of randomization with a Rankin Scale grade 3
                       or less

                    -  With normal computed tomography (CT) scan or CT scan showing a brain infarct
                       (even hemorrhagic infarct)

               -  Peripheral embolism

          -  Atherosclerotic plaque in the thoracic aorta is defined as wall thickness ≥ 4 mm where
             the protruding material is the largest, measured at transesophageal echocardiography
             with multiplane transducer or a plaque less than 4 mm but with mobile component.

          -  Informed consent signed

          -  Life expectancy &gt; 3 years

        Exclusion Criteria:

          -  Other causes of embolism:

               -  Cardiac: endocarditis, atrial fibrillation, intra-cardiac thrombus, valvular
                  prosthesis, rheumatic valvulopathy, left ventricular aneurysm, or ejection
                  fraction less than 25%

               -  Atherosclerotic stenosis ipsilateral to the embolic territory: internal carotid
                  artery stenosis greater than 70%, or severe (judgment of the investigator)
                  intracranial stenosis, or scheduled carotid endarterectomy (in that case
                  inclusion is possible 30 days after the procedure)

               -  Uncommon causes: dissection, vasculitis, procoagulant state, or sickle cell
                  disease

          -  Other exclusion criteria:

               -  Intercurrent illness with life expectancy less than 36 months

               -  Pregnancy and non-menopausal women

               -  Unwillingness to participate

               -  Poor medication compliance expected

               -  Toxicomania

               -  Absolute indication for anticoagulant therapy (e.g. atrial fibrillation,
                  intracardiac thrombus, prosthetic valve)

               -  Scheduled for carotid endarterectomy (randomization is possible 30 days after
                  endarterectomy)

          -  CT scan with an intracranial lesion other than brain infarction (space occupying mass,
             intracranial hemorrhage)

          -  Transesophageal echocardiography (TEE) with plaque ≥ 4 mm in thickness distal to the
             supposed embolized artery (judgement of the investigator).

          -  Contraindication to clopidogrel, aspirin, and oral anticoagulants
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre Amarenco, Pr, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Stroke Research Institute-Austin Health</name>
      <address>
        <city>Heidelberg Heights</city>
        <zip>Vic 3081</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bichat Hospital Head of Neurology Department</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>France</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 6, 2005</study_first_submitted>
  <study_first_submitted_qc>October 6, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 10, 2005</study_first_posted>
  <last_update_submitted>July 6, 2012</last_update_submitted>
  <last_update_submitted_qc>July 6, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 10, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TIA/Brain infarct</keyword>
  <keyword>and plaque&gt;4mm in the aortic arch</keyword>
  <keyword>Or peripheral embolism</keyword>
  <keyword>and plaque&gt;4 mm in the thoracic aorta</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Embolism</mesh_term>
    <mesh_term>Ischemic Attack, Transient</mesh_term>
    <mesh_term>Brain Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Warfarin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

